{"id":780886,"date":"2023-08-30T07:42:56","date_gmt":"2023-08-30T11:42:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/"},"modified":"2023-08-30T07:42:56","modified_gmt":"2023-08-30T11:42:56","slug":"graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/","title":{"rendered":"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023"},"content":{"rendered":"
\n

THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) — Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the \u201cCompany\u201d or \u201cGraf\u201d), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the \u201cBusiness Combination\u201d) with NKGen Biotech, Inc. (\u201cNKGen\u201d and such special meeting, the \u201cSpecial Meeting\u201d), which is scheduled to occur at 10:00 a.m., Eastern time, on August 30, 2023, and to reconvene the Special Meeting at 10:30 a.m., Eastern time, on September 8, 2023. The Special Meeting will still be held virtually at https:\/\/www.cstproxy.com\/grafiv\/sm2023<\/a><\/u>.<\/p>\n

The Company has received overwhelming support for the approval of the Business Combination and has received enough votes to date via proxy to approve each of the proposals to be presented at the Special Meeting. However, the Company has decided to adjourn the Special Meeting in order to provide additional time to continue its efforts to obtain additional financing, which may be in the form of equity, debt, grants or other equity-linked securities or derivatives, needed to satisfy the $50 million minimum cash condition under the agreement and plan of merger entered into in connection with the Business Combination, which may be waived by NKGen, in its sole discretion.<\/p>\n

In connection with the adjournment of the Special Meeting, the Company is reopening and extending the deadline for its stockholders to exercise their right to redeem their shares of common stock for their pro rata portion of the funds available in the Company\u2019s trust account, or to withdraw any previously delivered demand for redemption, to 5:00 p.m., Eastern time, on September 6, 2023 (two business days before the adjourned Special Meeting). If a stockholder has previously submitted a request to redeem its shares of common stock in connection with the Special Meeting and would like to reverse such request, such stockholder may contact the Company’s transfer agent, Continental Stock Transfer & Trust Company, at SPACredemptions@continentalstock.com.<\/p>\n

Stockholders of record as of August 7, 2023 are entitled to vote at the Special Meeting. Stockholders who have not yet done so are encouraged to vote as soon as possible. Stockholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not to take any further action. If any stockholders have questions or need assistance in connection with the Special Meeting, please contact the Company\u2019s proxy solicitor, Morrow Sodali LLC, by calling (800) 662-5200, or banks and brokers can call collect at (203) 658-9400, or by emailing GFOR.info@morrowsodali.com<\/a>.<\/p>\n

\n About Graf Acquisition Corp. IV <\/strong>\n <\/p>\n

Graf is a blank-check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.<\/p>\n

\n About NKGen<\/strong>\n <\/p>\n

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapies. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit\u00a0www.nkgenbiotech.com.<\/p>\n

\n Additional Information and Where to Find It <\/strong>\n <\/p>\n

The proposed Business Combination will be submitted to stockholders of Graf for their consideration at the Special Meeting. Graf has filed a registration statement on Form S-4 (the \u201cRegistration Statement\u201d) with the Securities and Exchange Commission (the \u201cSEC\u201d) relating to the proposed Business Combination, which includes both a definitive prospectus with respect to the securities of the post-combination company (\u201cNew NKGen\u201d) to be issued in connection with the proposed Business Combination and a proxy statement that was distributed to Graf\u2019s stockholders in connection with Graf\u2019s solicitation of proxies for the vote by its stockholders in connection with the proposed Business Combination and other matters as described in the Registration Statement. The Registration Statement was declared effective by the SEC and Graf mailed the definitive proxy statement\/prospectus to its stockholders as of the record date established for voting on the proposed Business Combination. Graf urges its investors, stockholders and other interested persons to read the definitive proxy statement\/prospectus, as well as other documents filed by Graf with the SEC, because these documents contain important information about Graf, NKGen and the proposed Business Combination. Stockholders may obtain a copy of the definitive proxy statement\/prospectus, as well as other documents filed with the SEC regarding the proposed Business Combination and other documents filed by Graf with the SEC, without charge, at the SEC\u2019s website located at www.sec.gov or by directing a request to: Graf Acquisition Corp. IV, 1790 Hughes Landing Blvd., Suite 400, The Woodlands, TX 77380.<\/p>\n

\n Participants in the Solicitation <\/strong>\n <\/p>\n

Graf and NKGen and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the proposed Business Combination under the rules of the SEC. Information about the directors and executive officers of Graf is set forth in the definitive proxy statement\/prospectus. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of Graf stockholders in connection with the proposed Business Combination is set forth in the definitive proxy statement\/prospectus. Stockholders, potential investors and other interested persons should read the definitive proxy statement\/prospectus carefully before making any voting or investment decisions. These documents can be obtained free of charge from the sources indicated above.<\/p>\n

\n No Offer or Solicitation<\/strong>\n <\/p>\n

This press release shall not constitute a proxy statement or a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business Combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities, in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.<\/p>\n

\n Forward-Looking Statements <\/strong>
\n
This press release includes forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the United States Private Securities Litigation Reform Act of 1995. These statements may be preceded by, followed by or include the words \u201cbelieves,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cprojects,\u201d \u201cforecasts,\u201d \u201coutlook,\u201d \u201cfuture,\u201d \u201cfurther,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201cseeks,\u201d \u201cseems,\u201d \u201ctargets,\u201d \u201cplans,\u201d \u201cscheduled,\u201d \u201canticipates,\u201d \u201cintends\u201d or similar expressions. These statements are based on the beliefs and assumptions of the management of Graf and NKGen. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, including changes in domestic and foreign business, market, financial, political and legal conditions, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors that may affect actual results or outcomes include, among others, the inability of the parties to successfully or timely consummate the proposed Business Combination; the failure to satisfy the conditions to the consummation of the proposed Business Combination, including but not limited to the approval of the merger agreement by Graf\u2019s stockholders, the satisfaction of the minimum cash condition, the compliance with the acquiror closing cash amount and the receipt of certain governmental and regulatory approvals; the inability to obtain any PIPE investments; the inability to raise or obtain sufficient funds to continue NKGen\u2019s operations through the consummation of the proposed Business Combination; the inability to recognize the anticipated benefits of the proposed Business Combination; the amount of redemption requests made by Graf\u2019s public stockholders; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, and the ability to maintain the listing of New NKGen\u2019s securities on a national securities exchange; and those factors discussed under the heading \u201cRisk Factors\u201d in the Registration Statement and other documents of Graf filed, or to be filed, with the SEC. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can Graf or NKGen assess the impact of all such risk factors on the businesses of Graf and NKGen prior to the proposed Business Combination, and New NKGen following the proposed Business Combination, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to Graf or NKGen or persons acting on their behalf are expressly qualified in their entirety by the foregoing cautionary statements. Graf and NKGen prior to the proposed Business Combination, and New NKGen following the proposed Business Combination, undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

Internal Contact:<\/strong>
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications
NKGen Biotech, Inc.
dchua@nkgenbiotech.com<\/a><\/u><\/p>\n

Sabrina McKee
Chief Financial Officer and EVP, Strategy
Graf Acquisition Corp. IV
sabrina@grafacq.com<\/a><\/p>\n

\n External Contacts:<\/strong>
\n
Chris Calabrese
Managing Director
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com<\/a><\/u><\/p>\n

Kevin Gardner
Managing Director
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com<\/a><\/u><\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) — Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the \u201cCompany\u201d or \u201cGraf\u201d), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the \u201cBusiness Combination\u201d) with NKGen Biotech, Inc. (\u201cNKGen\u201d and such special meeting, the \u201cSpecial Meeting\u201d), which is scheduled to occur at 10:00 a.m., Eastern time, on August 30, 2023, and to reconvene the Special Meeting at 10:30 a.m., Eastern time, on September 8, 2023. The Special Meeting will still be held virtually at https:\/\/www.cstproxy.com\/grafiv\/sm2023. The Company has received overwhelming support for the approval of the Business Combination and has … <\/p>\n

Continue reading “Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-780886","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGraf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) — Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the \u201cCompany\u201d or \u201cGraf\u201d), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the \u201cBusiness Combination\u201d) with NKGen Biotech, Inc. (\u201cNKGen\u201d and such special meeting, the \u201cSpecial Meeting\u201d), which is scheduled to occur at 10:00 a.m., Eastern time, on August 30, 2023, and to reconvene the Special Meeting at 10:30 a.m., Eastern time, on September 8, 2023. The Special Meeting will still be held virtually at https:\/\/www.cstproxy.com\/grafiv\/sm2023. The Company has received overwhelming support for the approval of the Business Combination and has … Continue reading "Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T11:42:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzM5MSM1Nzg5OTYwIzUwMDA3MDg1OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023\",\"datePublished\":\"2023-08-30T11:42:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/\"},\"wordCount\":1579,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzM5MSM1Nzg5OTYwIzUwMDA3MDg1OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/\",\"name\":\"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzM5MSM1Nzg5OTYwIzUwMDA3MDg1OA==\",\"datePublished\":\"2023-08-30T11:42:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzM5MSM1Nzg5OTYwIzUwMDA3MDg1OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzM5MSM1Nzg5OTYwIzUwMDA3MDg1OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/","og_locale":"en_US","og_type":"article","og_title":"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023 - Market Newsdesk","og_description":"THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) — Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the \u201cCompany\u201d or \u201cGraf\u201d), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the \u201cBusiness Combination\u201d) with NKGen Biotech, Inc. (\u201cNKGen\u201d and such special meeting, the \u201cSpecial Meeting\u201d), which is scheduled to occur at 10:00 a.m., Eastern time, on August 30, 2023, and to reconvene the Special Meeting at 10:30 a.m., Eastern time, on September 8, 2023. The Special Meeting will still be held virtually at https:\/\/www.cstproxy.com\/grafiv\/sm2023. The Company has received overwhelming support for the approval of the Business Combination and has … Continue reading \"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T11:42:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzM5MSM1Nzg5OTYwIzUwMDA3MDg1OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023","datePublished":"2023-08-30T11:42:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/"},"wordCount":1579,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzM5MSM1Nzg5OTYwIzUwMDA3MDg1OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/","name":"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzM5MSM1Nzg5OTYwIzUwMDA3MDg1OA==","datePublished":"2023-08-30T11:42:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzM5MSM1Nzg5OTYwIzUwMDA3MDg1OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzM5MSM1Nzg5OTYwIzUwMDA3MDg1OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/graf-acquisition-corp-iv-announces-intent-to-adjourn-special-meeting-to-approve-business-combination-with-nkgen-biotech-inc-to-september-8-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=780886"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780886\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=780886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=780886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=780886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}